Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (481)	4/9/1999 7:32:00 AM
From: Dr. John M. de Castro	Read Replies (1) of 1494

Diabetic Peripheral Neuropathy Competitor Fails NTII's memantine now has one less competitor for this huge market. Friday April 9, 3:06 am Eastern Time Genentech Phase 3 trial fails to meet goals SAN FRANCISCO, Calif., April 9 (Reuters) - Genentech Inc. said Friday the Phase III clinical trial of its recombinant human nerve growth factor for use in treating patients with diabetic peripheral neuropathy did not meet its objectives. The biotechnology firm said in a statement that it did not intend to file a biologics license application with the U.S. Food and Drug Administration. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next